Partial Epigenetic Reprogramming (Yamanaka Factors)
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Findings are limited to mouse and cell/tissue models (Cell 2025, PNAS/Nature preclinical studies); the only authorized human trial as of 2026 targets a specific eye disease and has not reported results, so there is no human longevity evidence yet.
Reference only. Not medical advice.
Partial epigenetic reprogramming refers to briefly and repeatedly activating some or all of the four Yamanaka factors (often just Oct4, Sox2, and Klf4, abbreviated OSK) inside adult cells, with the goal of resetting age-associated changes in DNA methylation and gene expression without pushing the cell all the way back to a pluripotent, identity-less state. The underlying theory, associated with researchers such as David Sinclair, holds that aging is substantially a loss of epigenetic information, and that restoring a more youthful epigenetic pattern could reverse multiple hallmarks of aging at once rather than treating one disease pathway at a time. Evidence to date is almost entirely preclinical. Studies in mice have used cyclic OSK expression delivered by adeno-associated virus (AAV) to extend remaining lifespan, improve vision after optic nerve injury, and reverse markers of aging in kidney, muscle, and brain tissue. A 2025 Cell paper found that a pattern of 'mesenchymal drift' in gene expression, seen across dozens of human tissues and diseases and correlated with worse survival, could be reduced by Yamanaka factor-induced partial reprogramming in cell and tissue models. No completed human trial has tested partial reprogramming for aging or age-related disease as of mid-2026. The first authorized human study, from Life Biosciences, targets a narrow ophthalmic use (optic nerve damage from glaucoma and NAION) rather than systemic aging, and was cleared by the FDA to begin only in January 2026. Because reprogramming factors, especially c-Myc, are associated with cancer risk, and because AAV gene therapy carries its own safety history, this remains a research-stage approach. It is not available as an approved therapy anywhere, and self-administered or clinic-marketed 'reprogramming' products for consumers are not backed by human safety or efficacy data.
Partial epigenetic reprogramming refers to briefly and repeatedly activating some or all of the four Yamanaka factors (often just Oct4, Sox2, and Klf4, abbreviated OSK) inside adult cells.
Safety in detail
Yamanaka factors include the oncogene c-Myc, and uncontrolled or non-cyclic reprogramming can produce teratomas or dysplasia in animal models; no long-term human safety data exist, and unregulated clinics offering 'reprogramming' treatments should be treated with skepticism.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
In 2006, Shinya Yamanaka's laboratory in Kyoto showed that four transcription factors, Oct4, Sox2, Klf4, and c-Myc, could convert adult mouse cells into induced pluripotent stem cells, work that earned him a share of the 2012 Nobel Prize. Full reprogramming erases cell identity, which is useful for stem cell science but dangerous in a living body because it can cause teratomas. Around 2016, researchers including Juan Carlos Izpisua Belmonte's group began testing brief, cyclic pulses of these factors, dubbed partial reprogramming, in live mice, aiming to erase epigenetic age markers while letting cells keep their tissue identity. Since then the field has moved from whole animal lifespan studies toward organ specific and viral delivery methods, with the first human clinical trial authorized only in 2026.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Partial Epigenetic Reprogramming (Yamanaka Factors). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.